A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improving track record of beating ...

Johnson & Johnson (NYSE ... point happened after the late 2021 approval for the treatment of bipolar depression. Caplyta is on track to generate nearly $700 million in net sales in 2024 and ...

Johnson & Johnson will pay Intra-Cellular shareholders ... which treats schizophrenia and bipolar I and II depression. The company also has other drugs in the pipeline to treat Alzheimer's Disease ...

The deal would add to J & J’s portfolio lumateperone, an Intra-Cellular drug branded Caplyta, a pill that treats bipolar depression and schizophrenia. Analysts predict the drug’s sales could ...

Johnson & Johnson (J&J ... Its shares rose following a recent settlement with Sandoz over Caplyta, a bipolar depression medication. Meanwhile, J&J's market capitalisation reportedly stands ...